<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Artis Ventures - Medium]]></title>
        <description><![CDATA[ARTIS Ventures (AV) partners with entrepreneurs who are driven to impact the world by reshaping and reinventing industries. The team supports its portfolio companies through their entire life-cycle, from initial venture investment to public offering and beyond. - Medium]]></description>
        <link>https://medium.com/artis-ventures?source=rss----44d5d2505761---4</link>
        <image>
            <url>https://cdn-images-1.medium.com/proxy/1*TGH72Nnw24QL3iV9IOm4VA.png</url>
            <title>Artis Ventures - Medium</title>
            <link>https://medium.com/artis-ventures?source=rss----44d5d2505761---4</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 02:02:57 GMT</lastBuildDate>
        <atom:link href="https://medium.com/feed/artis-ventures" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[ARTIS Appoints New Principal, Welcomes Ameena El-Bibany to Team]]></title>
            <link>https://medium.com/artis-ventures/artis-appoints-new-principal-welcomes-ameena-el-bibany-to-team-5dcbeaf12941?source=rss----44d5d2505761---4</link>
            <guid isPermaLink="false">https://medium.com/p/5dcbeaf12941</guid>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[science]]></category>
            <dc:creator><![CDATA[Vasudev Bailey]]></dc:creator>
            <pubDate>Thu, 12 Dec 2019 00:21:09 GMT</pubDate>
            <atom:updated>2019-12-12T00:21:09.691Z</atom:updated>
            <content:encoded><![CDATA[<h3>ARTIS recently welcomed <a href="https://www.linkedin.com/in/aelbibany/">Ameena El-Bibany</a> to the ARTIS family as a Principal. Ameena will be helping to source and lead investments across TechBio as well as supporting our portfolio companies.</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*zHOBkwcw0DHm70CjPtHI8g.jpeg" /></figure><p>Prior to ARTIS, Ameena spent over five years investing at the intersection of technology and biology as a Partner at Rising Tide VC, where she helped launch the first two pooled funds and began and built the firm’s health and bio investment practice. She has invested in, and worked with, companies spanning personalized medicine, synthetic biology, computational biology, and more.</p><p>Her passion for bridging academia and industry to create lasting impact is a culmination of her early life growing up on Stanford campus immersed in tech, as well as her early technical career as a geneticist. She began her career in R&amp;D at<a href="https://www.novozymes.com/en"> Novozymes</a>, a world leader in bio innovation, and has conducted research across DNA damage and repair in longevity, microbiome diversity, and stem cell induction and stabilization. She has received multiple competitive grants funded by the<a href="https://www.nsf.gov/"> National Science Foundation</a> for research done at the<a href="https://www.calacademy.org/"> California Academy of Sciences</a> and the<a href="http://www.bios.edu/"> Bermuda Institute of Ocean Sciences</a>, and was an awardee of the<a href="https://www.nsfgrfp.org/"> National Science Foundation Graduate Research Fellowship Program</a>. Ameena holds a B.S. in Genetics from the<a href="https://www.ucdavis.edu/"> University of California, Davis</a>.</p><p>Ameena has been collaborating with the ARTIS team for years, and we’ve had the opportunity to work together through common portfolio companies<a href="https://taelifesciences.com/"> TAE Life Sciences</a> and<a href="http://www.unnaturalproducts.com/"> Unnatural Products, Inc.</a> Her deep technical knowledge, ability to resonate with founders, and thoughtful approach to building companies, makes her a natural fit for ARTIS as we pave our way in TechBio.</p><p>We are glad to have you, Ameena!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5dcbeaf12941" width="1" height="1" alt=""><hr><p><a href="https://medium.com/artis-ventures/artis-appoints-new-principal-welcomes-ameena-el-bibany-to-team-5dcbeaf12941">ARTIS Appoints New Principal, Welcomes Ameena El-Bibany to Team</a> was originally published in <a href="https://medium.com/artis-ventures">Artis Ventures</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Fabric Genomics: Moore’s Law & The Coming TechBio Revolution]]></title>
            <link>https://medium.com/artis-ventures/omicia-moores-law-the-coming-genomics-revolution-2cd31c8e5cd0?source=rss----44d5d2505761---4</link>
            <guid isPermaLink="false">https://medium.com/p/2cd31c8e5cd0</guid>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[genomics]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[venture-capital]]></category>
            <dc:creator><![CDATA[stuart peterson]]></dc:creator>
            <pubDate>Wed, 08 Jun 2016 12:06:03 GMT</pubDate>
            <atom:updated>2019-11-18T21:36:28.034Z</atom:updated>
            <content:encoded><![CDATA[<p>For the last 50 years, Moore’s Law has been almost an absolute constant for measuring progress in technology. With astounding predictability, Gordon Moore’s famous observation in 1965 on the doubling of components per chip became a sort of self-fulfilling prophecy has served as an industry benchmark. Recently, there’s been renewed discussion of limits to Moore’s law, and this has led to more for research and investment in new computing paradigms like Quantum Computing.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/973/1*V5TDAUyVTHJzwGF3w7ZvWA.png" /></figure><p>The end result of this methodical and exponential increase in computing power has been significant deflation in the cost of computing. Software companies and their end users have reaped massive benefits of this cost reduction by being able to develop ever more advanced applications. It’s easy to forget that the <a href="http://www.anandtech.com/show/9686/the-apple-iphone-6s-and-iphone-6s-plus-review/5">iPhone 6s in your pocket</a> has substantially more computing power than <a href="http://www.top500.org/site/48052">IBM’s Deep Blue</a> that defeated Gary Kasparov in chess in 1997.</p><p>Moore’s Law is rightfully cited as one of the standards of technological progress. What’s often overlooked is the dramatic decline in the price of sequencing the human genome. It cost <strong>$95,263,072</strong> to sequence one human genome in 2001. By 2015, the cost dropped to <strong>$1,245.</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*p-iYFxU-Xu7b8uB3-roBww.jpeg" /></figure><p>Unfortunately for patients, the cost reduction in genomic sequencing is only half the solution. Sequencing a genome alone doesn’t provide insights, the output is essentially a large data file. To take advantage of the information, one has to manually analyze and interpret the sequenced genome through an expensive, laborious process. This is akin to Intel releasing a next generation i7 processor in 2016, but the only software available to run on it is MS-DOS.</p><blockquote><strong>“It takes 200 person hours for [clinical] interpretation of [of a human genome] which is more than $20,000,” </strong>— Michael Synder, Director for Genomics and Personalized Medicine at Stanford</blockquote><p>Enter <a href="http://www.omicia.com/">F</a>abric Genomics.</p><p><a href="http://www.omicia.com/">F</a>abric’s scalable software platform enables affordable genomic interpretation for cases like difficult childhood diseases, diagnoses for rare diseases, cancer screening, or cardiovascular disease risk.</p><p>We led <a href="http://www.omicia.com/">F</a>abric’s Series A because we saw the enormous potential available to take both the power of genomic sequencing and it’s declining cost (hardware) and pair it with <a href="http://www.omicia.com/">F</a>abric’s scalable platform (software) to bring clinically relevant information to patients and their physicians. Their progress has been impressive:</p><ul><li>Dramatic reductions in the cost of clinical interpretation of the human genome</li><li>Partnering with the Genomics England to provide clinical interpretation services for the <a href="http://www.genomicsengland.co.uk/the-100000-genomes-project/">100,000 Genomes project</a></li><li>A diverse customer base including over 500 research, pharma, and clinical diagnostics labs</li></ul><p>Today’s announcement of a $23M Series B is another strong validation of <a href="http://www.omicia.com/">F</a>abric’s accomplished team, their world-class product, and the opportunity to standardize genomic interpretation across the world to deliver truly personalized medicine. We’re thrilled to be joined by a great group of co-investors, healthcare system stakeholders, and strategic international partners to bring <a href="http://www.omicia.com/">F</a>abric’s platform to the world.</p><p>At ARTIS, we look for companies that can deliver innovative solutions on a global scale to materially impact peoples’ lives. There is an immense opportunity to deliver significantly improved health outcomes using personalized medicine. We’re excited to watch <a href="http://www.omicia.com/">F</a>abric deliver on this promise.</p><p><strong>Stuart Peterson<br></strong><em>Partner, Artis Ventures</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2cd31c8e5cd0" width="1" height="1" alt=""><hr><p><a href="https://medium.com/artis-ventures/omicia-moores-law-the-coming-genomics-revolution-2cd31c8e5cd0">Fabric Genomics: Moore’s Law &amp; The Coming TechBio Revolution</a> was originally published in <a href="https://medium.com/artis-ventures">Artis Ventures</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Congratulations Stemcentrx]]></title>
            <link>https://medium.com/artis-ventures/congratulations-stemcentrx-e65576762d28?source=rss----44d5d2505761---4</link>
            <guid isPermaLink="false">https://medium.com/p/e65576762d28</guid>
            <category><![CDATA[disruption]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[stemcentrx]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[biotechnology]]></category>
            <dc:creator><![CDATA[stuart peterson]]></dc:creator>
            <pubDate>Thu, 28 Apr 2016 12:23:05 GMT</pubDate>
            <atom:updated>2019-01-15T20:21:46.372Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/671/1*2Spae0rNuz747KLSOVBjaQ.jpeg" /></figure><p>In March of 2011, ARTIS and our affiliates led the first institutional round of financing at Stemcentrx with a $18M investment in a total round of $25M. Stemcentrx represented everything we look for within our portfolio companies: a talented, passionate team addressing a hard problem we care deeply about with a differentiated approach showing promising early results. This morning, <a href="https://news.abbvie.com/news/abbvie-to-expand-oncology-presence-through-acquisition-stemcentrx-and-its-novel-late-stage-rova-t-compound-for-small-cell-lung-cancer.htm?icid=stemcentrx-showcase">AbbVie announced its acquisition of Stemcentrx for as much as $10.2 billion</a>. This outcome represents the largest private transaction in the history of venture-backed biotech and the second largest takeout of any private company in the history of venture. More importantly, it represents a spectacular milestone for Scott, Dan, and Brian and all those willing to play the long game, tackling humanity’s hardest problems with deep science.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*gPC-f2kuBrfTgLV2_lm85g.png" /></figure><p>You may be reading this in an attempt to understand how the largest venture-backed biotech acquisition in history could have happened with a company you’ve likely heard precious little about. Digging a bit deeper, you’ll find this has been by design all along.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/992/1*cK_KkCuzj4eNxHWQVMlGBg.png" /></figure><p>From their earliest stages, the team has stayed heads-down, focused with a singular purpose: embracing the cancer stem cell (CSC) paradigm to discover novel therapies with the ultimate goal of <strong>curing patients with solid tumors</strong>. All the while, and often in stark contrast to other startups seeking adoration before producing anything of value, the Stemcentrx team has been willing to let their results define them rather than their words. See our Blog post from September of last year for more details: “<a href="http://www.artisventures.com/blog/stemcentrx-charges-out-of-stealth-science-does-all-the-talking/">Stemcentrx Charges Out of Stealth: Science Does All the Talking.</a>”</p><p>Cancer research is often used as the yardstick by which difficult problems are measured, consuming over $500 billion in research dollars since Nixon first declared “War on Cancer” in 1971. We couldn’t be prouder to have had the opportunity to partner in the journey with Stemcentrx since 2011 as their first institutional investor, and it has been a privilege for me to serve on the board of directors.</p><p>In the last decade, it’s been all too frequent for investors to shun “hard science/tech” and not back startups believed to have high “technical risk” with long gestation periods. When we made the decision to partner with Stemcentrx, other tech-focused venture funds went so far as to announce publicly they would invest in anything but life science. Only now are many of these same funds reversing course. This trend is only set to accelerate as we are in the midst of a technological renaissance within the area of health and wellness driven by multiple tailwinds: affordably mapping the human genome and the DNA of all living systems, growing adoption of targeted therapeutics and immunotherapies, digitization of healthcare and movement towards more transparent &amp; health-conscious diets.</p><p>Today’s outcome is a wake up call to those that continue to ignore these tailwinds and instead choose to fund yet another consumer app with the hope they will once again generate an instant buzz and rapidly skyrocket to millions of users. We cannot complain as an industry about the lack of value creation, enduring companies, and liquidity events if we aren’t willing to solve big problems. At ARTIS, we’ve built a history of enthusiastically backing teams across multiple industries addressing these sorts of challenges; whether it’s YouTube revolutionizing digital media, Stemcentrx’s novel cancer therapeutics, or emerging companies with the promise to either upend or create entirely new industries like <a href="http://www.modernmeadow.com/">Modern Meadow</a>, <a href="http://www.cohesity.com/">Cohesity</a>, <a href="http://www.omicia.com/">Fabric</a> Genomics, and others.</p><p>The conventional wisdom that has infected Silicon Valley is that “real innovation” is over, tech is “out of new ideas,” and the entire industry is overvalued and ripe for a massive correction. We’re content to leave the armchair quarterbacking to others while we continue to partner with entrepreneurs working on life-changing breakthroughs that will materially improve the world around them.</p><p>If you’re one of these teams not afraid to tackle hard problems with technical risk that have enormous potential to both move the world forward and be a smashing commercial success, please <a href="/service/mailto:contact@artisventures.com">contact us</a>.</p><p><strong>Stuart Peterson</strong></p><p><em>Founding Partner, Artis Ventures<br>First institutional lead investor and outside board member, Stemcentrx</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e65576762d28" width="1" height="1" alt=""><hr><p><a href="https://medium.com/artis-ventures/congratulations-stemcentrx-e65576762d28">Congratulations Stemcentrx</a> was originally published in <a href="https://medium.com/artis-ventures">Artis Ventures</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Micro-Marketing Services will accelerate growth for agile marketing teams]]></title>
            <link>https://medium.com/artis-ventures/micro-marketing-services-will-accelerate-growth-for-agile-marketing-teams-2f3aed5bddc5?source=rss----44d5d2505761---4</link>
            <guid isPermaLink="false">https://medium.com/p/2f3aed5bddc5</guid>
            <category><![CDATA[microservices]]></category>
            <category><![CDATA[growth]]></category>
            <category><![CDATA[marketing]]></category>
            <dc:creator><![CDATA[Austin Walne]]></dc:creator>
            <pubDate>Wed, 27 Apr 2016 20:37:30 GMT</pubDate>
            <atom:updated>2016-02-08T21:48:37.097Z</atom:updated>
            <content:encoded><![CDATA[<p>Matt Miller, partner at Sequoia Capital, recently penned an op-ed titled “<a href="http://blogs.wsj.com/cio/2015/10/05/innovate-or-die-the-rise-of-microservices/">Innovate or Die: The Rise of Microservices</a>” where he describes a new software engineering paradigm of microservices, “an approach where large applications are broken down into small, loosely coupled and composable autonomous pieces,” that are radically changing how software is built, deployed, and maintained.</p><p>While web-scale companies like Google, Amazon, and Facebook have been running microservices for years, three key technology developments are facilitating the current mass adoption in companies large and small:</p><ol><li>Containers (standardization of services that simplifies the often difficult integration process in software infrastructure — e.g. <a href="https://www.docker.com/">Docker</a>)</li><li>APIs (“application programming interfaces” that help facilitate integration between otherwise distinct applications — e.g. REST, JSON)</li><li>Scalable cloud infrastructure (Cloud Service Providers, have aggressively cut the costs of their computing platforms — e.g. AWS, Google Compute)</li></ol><p>These developments, however, are not limited to engineering and IT teams.</p><p>It’s been well documented that online marketing is not only changing; the change is <em>accelerating</em>. CMOs and their teams are working in overdrive to uncover and exploit new tactics to give them an advantage in acquiring new customers and retaining their existing ones. At the same time, the lifecycle of effective marketing channels is decreasing as each channel becomes saturated at an ever increasing pace.</p><p>Established channels like SEO, Email, Facebook, Display are <a href="http://www.coelevate.com/essays/how-marketing-is-changing">undergoing substantial structural changes</a>. Nascent channels like messaging apps, Instagram, and Product Hunt have created new distribution opportunities. Pinterest &amp; Snapchat are beginning to monetize their services by opening up to advertisers (both services already provide ample organic reach.) The re-emergence of podcasts, promise of VR, and more will provide marketers continually refreshing green fields to sow for prospects.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/750/1*GGomNztpSCryCdFLJ5KFCQ.png" /><figcaption>“The lifecycle of marketing channels is accelerating. It’s good to understand that every successful channel is a dying channel” — <a href="https://medium.com/u/c81281276bc9">Peter van Sabben</a></figcaption></figure><p>To succeed in an environment of rapid change, marketers must adopt a growth mentality, <a href="https://medium.com/agile-marketing">an agile processes to guide their workflow</a>, and effectively utilize the latest technologies and tools. Mozilla CMO, Jascha Kaykas-Wolff captures this sentiment:</p><blockquote><a href="https://medium.com/agile-marketing/structural-minds-vs-exploratory-minds-b9ec5995e638#.yk6kz7rkm">“Marketing and innovating for new opportunities is a series of adjustments to many small failures, where even a 5% success rate could be considered an A+, not 90% or better!”</a></blockquote><p>Legacy marketing suites have long promised integrated tools to allow marketing teams to unify their analytics, a/b testing, marketing automation, and reporting under one banner. The promises of unified data and seamless integrations are often oversold by enterprise salespeople and leave marketing teams in rigid systems unable to adapt.</p><p><strong>Enter Micro-Marketing Services.</strong></p><p>Micro-Marketing Services are beginning to see widespread adoption inside marketing teams thanks to similar technology developments as their neighbors in engineering.</p><ol><li>Tag Managers: Any developer who’s been tasked with “tagging” their website or product has felt the pain associated with instrumenting analytics and other marketing code. Active demand generation teams fill backlogs of tasks for their dev teams who spend hours placing, testing, and removing tracking pixels and other custom code for every new service, ad-network, and marketing tool that comes along. <a href="https://www.google.com/analytics/tag-manager/">Google Tag Manager</a>, <a href="http://tealium.com/products/tealium-iq-tag-management-system/">Tealium,</a> and <a href="https://segment.com/">Segment</a> work like <a href="https://www.docker.com/">Docker</a> containers for marketers and simply the integration process.</li><li>APIs: Marketing services and applications have lagged behind engineering tools with public APIs; but have recently begun to catch up with major players like <a href="https://www.optimizely.com/">Optimizely</a> opening up APIs to allow developers to turn what began as a simple A/B testing platform into a delivery tool for personalized content tailored to users’ customizable attributes. Other tools like <a href="https://zapier.com/">Zapier</a> allow marketers to string together services that wouldn’t be able to otherwise connect.</li><li>Data Warehouses: Large enterprises commit substantial time and money to centralize data from multiple systems to establish a “single source of truth” for customer records. New services like <a href="https://www.getlytics.com/">Lytics‘ Customer Data Platform</a> or <a href="http://www.looker.com/">Looker</a> provide a repository of customer data like email, web, and social to create real-time profiles of your users. This data can be segmented, parsed, analyzed, and acted-upon by marketers or business analysts that doesn’t require teams of developers, data-scientists, or IT specialists to implement.</li></ol><p>Legacy enterprise technology providers must change how they build and deliver software or they will be eclipsed by their more nimble startup competitors. They will have to stop selling a nebulously defined “Product Cloud” and instead begin to offer distinct apps; much like Facebook has broken out Messenger and maintains separate, distinct identities for Instagram, Oculus, WhatsApp in an app constellation.</p><p>Marketing teams are already doing this, often going around their in-house procurement departments and paying for many of these services with corporate credit cards (as individual services are often in the $50–500 a month price range and are under the limits required of purchase orders.)</p><p>Micro-Marketing Services are further enabling marketing organizations to be more agile and adapt to the latest changes in customers’ product research, evaulation, buying, and using behavior. Marketers must utilize growth frameworks like <a href="http://sfagilemarketing.com/">Agile Marketing</a> to provide structure for their experimentation to continually innovate with their use of tactics &amp; technology or be left behind by their competition.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=2f3aed5bddc5" width="1" height="1" alt=""><hr><p><a href="https://medium.com/artis-ventures/micro-marketing-services-will-accelerate-growth-for-agile-marketing-teams-2f3aed5bddc5">Micro-Marketing Services will accelerate growth for agile marketing teams</a> was originally published in <a href="https://medium.com/artis-ventures">Artis Ventures</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>